ETF overview
The VanEck Biotech ETF (BBH) aims to closely reflect the price appreciation and income yield of the MVIS US Listed Biotech 25 Index (MVBBHTR), prior to the deduction of fees and expenses. This index monitors the aggregate performance of corporations involved in the research, manufacturing, promotion, and sale of medications derived from genetic insights and diagnostic technologies.
Fund facts
- Expense ratio
- 0.35%
- Fund assets
- 503.63M USD (all share classes)
- Issuer
- VanEck
- Inception date
- Dec 20, 2011
- Number of holdings
- 25
Breakdown
Holdings (25)
| Name | Ticker | Weight |
|---|---|---|
| Amgen Inc | AMGN | 16.13% |
| Gilead Sciences Inc | GILD | 13.81% |
| Vertex Pharmaceuticals Inc | VRTX | 7.94% |
| Moderna Inc | MRNA | 7.39% |
| Regeneron Pharmaceuticals Inc | REGN | 6.77% |
| Natera Inc | NTRA | 4.78% |
| Iqvia Holdings Inc | IQV | 4.47% |
| Argenx Se | ARGX | 4.02% |
| Illumina Inc | ILMN | 3.93% |
| Revolution Medicines Inc | RVMD | 3.86% |
| and 12 more | ||
Similar ETFs
- iShares Biotechnology ETFIBB · Overlap 65% · Expense ratio 0.44%
- Invesco Nasdaq Biotechnology ETFIBBQ · Overlap 58% · Expense ratio 0.19%
- Invesco NASDAQ Biotech UCITS ETFSBIO.L · Overlap 58% · Expense ratio 0.40%
- iShares Nasdaq US Biotechnology UCITS ETFBTEC.L · Overlap 58% · Expense ratio 0.35%
- MiraeAsset TIGER NASDAQ BIO ETF203780.KS · Overlap 57% · Expense ratio 0.30%
- Invesco Biotechnology & Genome ETFPBE · Overlap 43% · Expense ratio 0.59%
- First Trust NYSE Arca Biotechnology Index FundFBT · Overlap 41% · Expense ratio 0.55%
Overlap is the share of assets the two funds hold in common.
Historical returns do not guarantee future returns. This is not investment advice.
- Expense ratio
- 0.35%
- Fund assets
- 503.63M USD (all share classes)
- Issuer
- VanEck
- Inception date
- Dec 20, 2011
- Number of holdings
- 25
| Name | Ticker | Weight |
|---|---|---|
| Amgen Inc | AMGN | 16.13% |
| Gilead Sciences Inc | GILD | 13.81% |
| Vertex Pharmaceuticals Inc | VRTX | 7.94% |
| Moderna Inc | MRNA | 7.39% |
| Regeneron Pharmaceuticals Inc | REGN | 6.77% |
| Natera Inc | NTRA | 4.78% |
| Iqvia Holdings Inc | IQV | 4.47% |
| Argenx Se | ARGX | 4.02% |
| Illumina Inc | ILMN | 3.93% |
| Revolution Medicines Inc | RVMD | 3.86% |
| and 12 more | ||
The VanEck Biotech ETF (BBH) aims to closely reflect the price appreciation and income yield of the MVIS US Listed Biotech 25 Index (MVBBHTR), prior to the deduction of fees and expenses. This index monitors the aggregate performance of corporations involved in the research, manufacturing, promotion, and sale of medications derived from genetic insights and diagnostic technologies.
- iShares Biotechnology ETFIBB · Overlap 65% · Expense ratio 0.44%
- Invesco Nasdaq Biotechnology ETFIBBQ · Overlap 58% · Expense ratio 0.19%
- Invesco NASDAQ Biotech UCITS ETFSBIO.L · Overlap 58% · Expense ratio 0.40%
- iShares Nasdaq US Biotechnology UCITS ETFBTEC.L · Overlap 58% · Expense ratio 0.35%
- MiraeAsset TIGER NASDAQ BIO ETF203780.KS · Overlap 57% · Expense ratio 0.30%
- Invesco Biotechnology & Genome ETFPBE · Overlap 43% · Expense ratio 0.59%
- First Trust NYSE Arca Biotechnology Index FundFBT · Overlap 41% · Expense ratio 0.55%
Overlap is the share of assets the two funds hold in common.
Unlock all ETF data
Sign up for FreeUnlock all ETF data
Sign up for Free